Yi Bin Chen, MD
Hematology & Oncology · Boston, MANPI 1356332639
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $228,916 of the $252,464 with a category attached, or 90.7%. 20 manufacturers reported payments, led by Daiichi Sankyo Inc. at 38.7% of the total. Reporting peaked in 2021 at $89,996 and has fallen 53.9% since, to $41,508 in 2025. Among hematology & oncology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 205 payments — averaging $1231.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$98K
- Incyte Corporation$88K
- AstraZeneca$15K
- CSL Behring$11K
- Vectivbio AG$8K
- Modernatx, Inc.$8K
- plus $25K from 14 others
Across 81 payments — averaging $16,939 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$765K
- Incyte Corporation$267K
- AbbVie$153K
- Astellas Pharma Global Development$111K
- National Marrow Donor Program$61K
- Vectivbio AG$14K
- plus $400 from 1 others
What the payments were for
- Consulting fees$228,91691%
- Speaking & faculty fees$6,5503%
- Travel & lodging$11,9445%
- Food & beverage$5,0542%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 29 | $97,683 |
| Incyte Corporation | 119 | $87,627 |
| AstraZeneca | 7 | $14,500 |
| CSL Behring | 3 | $10,916 |
| Vectivbio AG | 1 | $8,250 |
| Modernatx, Inc. | 2 | $8,000 |
| Syndax Pharmaceuticals, Inc. | 3 | $7,165 |
| Pharmacosmos Therapeutics Inc. | 5 | $6,200 |
| Pharmacyclics LLC, An Abbvie Company | 10 | $3,494 |
| Aimmune Therapeutics, Inc. | 2 | $2,975 |
| Rigel Pharmaceuticals, Inc. | 3 | $2,152 |
| National Marrow Donor Program | 8 | $1,500 |
| Genentech USA, Inc. | 6 | $1,174 |
| ZOLL Medical Corporation | 1 | $450 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $112 |
| AbbVie | 1 | $84 |
| Genentech, Inc. | 1 | $77 |
| Bristol Myers Squibb | 1 | $42 |
| Gilead | 1 | $33 |
| Gamida Cell Inc. | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JAKAFI$32,190
- ULTOMIRIS$14,500
- NIKTIMVO$10,976
- REVUFORJ$7,165
- Monoferric$6,200
- VANFLYTa$4,133
- Enhertu$3,942
- IMBRUVICA$3,226
- VOWST$2,975
- Rezlidhia$2,107
- Tavalisse$2,107
- Defibrillator$450
- LIVTENCITY$112
How this compares
$252,464 in reported general payments places this provider in the 95th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 128 | $1,909,185 |
| IdhifaEnasidenib Mesylate | 12 | $405,782 |
| RezurockBelumosudil Mesylate | 14 | $278,349 |
| PrevymisLetermovir | 17 | $116,389 |
| Atovaquone | 20 | $4,848 |
| Famciclovir | 13 | $2,929 |
| Omeprazole | 12 | $315 |
| Morphine Sulfate | 11 | $281 |
| Lorazepam | 41 | $179 |
| Gabapentin | 22 | $158 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $105 |
| Prednisone | 21 | $90 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $87,627 | $1,909,185128 claims |
| Bristol Myers SquibbIdhifa | $42 | $405,78212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 374 hematology & oncology providers in Massachusetts.
Other hematology & oncology in Boston
- David ScaddenBoston$2.6M
- Sara TolaneyBoston$799K
- Matthew DavidsBoston$693K
- Julio HajdenbergBoston$583K
- Paul RichardsonBoston$523K
- Seth WanderBoston$464K
- Corey CutlerBoston$454K
- Hanny Al-SamkariBoston$412K
- Rupal BhattBoston$380K
- Matthew Vander HeidenBoston$355K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.